DK0566571T3 - Diagnose af metastatisk cancer ved hjælp af mts-1-genet - Google Patents

Diagnose af metastatisk cancer ved hjælp af mts-1-genet

Info

Publication number
DK0566571T3
DK0566571T3 DK91915859.2T DK91915859T DK0566571T3 DK 0566571 T3 DK0566571 T3 DK 0566571T3 DK 91915859 T DK91915859 T DK 91915859T DK 0566571 T3 DK0566571 T3 DK 0566571T3
Authority
DK
Denmark
Prior art keywords
mts
present
diagnosis
gene
protein
Prior art date
Application number
DK91915859.2T
Other languages
Danish (da)
English (en)
Inventor
Sayeeda Zain
Eugene Lukanidin
Original Assignee
Res Corp Technologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Corp Technologies Inc filed Critical Res Corp Technologies Inc
Application granted granted Critical
Publication of DK0566571T3 publication Critical patent/DK0566571T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4728—Calcium binding proteins, e.g. calmodulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Dermatology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
DK91915859.2T 1990-07-09 1991-07-09 Diagnose af metastatisk cancer ved hjælp af mts-1-genet DK0566571T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55060090A 1990-07-09 1990-07-09
PCT/US1991/004832 WO1992000757A1 (fr) 1990-07-09 1991-07-09 Diagnostic du cancer metastatique a l'aide du gene mts-1

Publications (1)

Publication Number Publication Date
DK0566571T3 true DK0566571T3 (da) 1997-12-15

Family

ID=24197845

Family Applications (1)

Application Number Title Priority Date Filing Date
DK91915859.2T DK0566571T3 (da) 1990-07-09 1991-07-09 Diagnose af metastatisk cancer ved hjælp af mts-1-genet

Country Status (7)

Country Link
EP (1) EP0566571B1 (fr)
JP (2) JP3398149B2 (fr)
AT (1) ATE152629T1 (fr)
CA (1) CA2086829A1 (fr)
DE (1) DE69126038T2 (fr)
DK (1) DK0566571T3 (fr)
WO (1) WO1992000757A1 (fr)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5700444A (en) * 1992-02-20 1997-12-23 Rhomed Incorporated Chemotactic peptide pharmaceutical applications
US5443816A (en) * 1990-08-08 1995-08-22 Rhomed Incorporated Peptide-metal ion pharmaceutical preparation and method
US5798257A (en) * 1990-07-09 1998-08-25 Research Corporation Technologies, Inc. Nucleic acid encoding human MTS-1 protein
US6638504B1 (en) * 1990-07-09 2003-10-28 Research Corporation Technologies, Inc. Methods for treating cancer
US5556609A (en) * 1992-02-20 1996-09-17 Rhomed Incorporated YIGSR peptide radiopharmaceutical applications
GB9311130D0 (en) * 1993-05-28 1993-07-14 Isis Innovation Tumor metastasis gene
AU694502B2 (en) * 1994-03-18 1998-07-23 Myriad Genetics, Inc. Mts gene, mutations therein, and methods for diagnosing cancer using mts gene sequence
RU2161309C2 (ru) * 1994-03-18 2000-12-27 Исследовательский Фонд Университета Юты, Мутации гена мтs в зародышевой линии и способ выявления предрасположенности к злокачественным опухолям в гене мтs
US5872007A (en) * 1995-02-17 1999-02-16 Hybridon, Inc. CAPL-specific oligonucleotides and methods of inhibiting metastatic cancer
WO1996039504A2 (fr) * 1995-06-06 1996-12-12 Novartis Ag Procede permettant la distinction entre cancers metastatiques et cancers non metastatiques, et polynucleotides et polypeptides utilises dans ce procede
GB9519275D0 (en) 1995-09-21 1995-11-22 Univ Dundee Substances and their therapeutic use
DE10229391A1 (de) * 2002-06-29 2004-01-29 Forschungszentrum Karlsruhe Gmbh METASTACHIP: ein Biochip zur Bestimmung des metastatischen Potentials von Tumoren
PL1799230T3 (pl) 2004-08-27 2013-05-31 Cyclacel Ltd Purynowe i pirymidynowe inhibitory CDK i ich zastosowanie do leczenia chorób autoimmunologicznych
RU2615684C2 (ru) 2010-06-14 2017-04-06 Ликера Биомед Са Специфическое антитело к s100a4 или его фрагмент (варианты), способ их получения (варианты), фармацевтическая композиция, их содержащая, гибридомная клеточная линия (варианты), конъюгат, композиция, способ предупреждения и/или лечения рака, метастазирования, ангиогенеза и воспалительных заболеваний, способ и набор для диагностики рака или заболевания, ассоциированного с воспалением, (варианты), способ детекции s100a4, способ создания индивидуальной терапии

Also Published As

Publication number Publication date
JP2003199589A (ja) 2003-07-15
DE69126038D1 (de) 1997-06-12
EP0566571A4 (fr) 1993-05-27
EP0566571B1 (fr) 1997-05-07
ATE152629T1 (de) 1997-05-15
DE69126038T2 (de) 1997-09-25
WO1992000757A1 (fr) 1992-01-23
EP0566571A1 (fr) 1993-10-27
JPH06500018A (ja) 1994-01-06
JP3398149B2 (ja) 2003-04-21
JP3527733B2 (ja) 2004-05-17
CA2086829A1 (fr) 1992-01-10

Similar Documents

Publication Publication Date Title
DK0566571T3 (da) Diagnose af metastatisk cancer ved hjælp af mts-1-genet
CA2042064A1 (fr) C-erbb-2 domaine exterieur : gp75
Harlamert et al. Thyroid transcription factor-1 and cytokeratins 7 and 20 in pulmonary and breast carcinoma
ES2185705T3 (es) Proteina bifuncional, preparacion y uso.
ATE229073T1 (de) Protein e25a, methoden zu dessen herstellung und anwendung
CA2164498A1 (fr) Essai pour ykl-40 comme marqueur de la degradation des constituants du tissu conjonctif de mammiferes
WO1999004265A3 (fr) Acides nucleiques et polypeptides associes au cancer
DE69929185D1 (de) Tumormarker
ATE206395T1 (de) Fluoreszierende porphyrin- und fluoreszierende phthalocyanin-polyethylenglykol-, polyol- und saccharidderivate als fluoreszierende sonden
Bordes et al. Carcinoembryonic antigen (CEA) and related antigens in blood cells and hematopoietic tissues
AP2000001917A0 (en) Gene encoding labyrinthin, a marker for cancer.
ES8501630A1 (es) Un metodo para detectar o vigilar el estado de una condicion patologica humana que implica proteina de tejido conjuntivo.
DK0991945T3 (da) Fremgangsmåde til identifikation af tumor-antigener med antistoffer i serum
Lamovec et al. Pleomorphic fibroma of tendon sheath
DK0495910T3 (da) Fremstilling og anvendelse af humant nm23-H2-protein og derimod rettede antistoffer
ATE288960T1 (de) Humanisierte monoklonale antikörper mit hoher affinität gegen tag-72
Khan et al. In vivo determinations of labelling index of metastatic colorectal carcinoma and normal colonic mucosa using intravenous infusions of bromodeoxyuridine
Sasaki et al. Breast cancer markers: comparison between sialyltransferase and human mammary epithelial antigens (HME-Ags) for the detection of human breast tumors grafted in nude mice
Ljung Radiotherapy of prostatic adenocarcinoma, with reference to local cure, characterization of residual tumour cells with assessment of adverse effects.
Truax et al. A method for demonstrating probable synthesis of protein by bone marrow cells
Yang et al. E-cadherin expression in thymomas
Franzen A two-dimensional gel electrophoretic study of proteins in tumours of the lung and breast.
Che et al. STUDY ON SIGNIFICANCE OF EXPRESSION OF BASIC FIBROBLAST GROWTH FACTOR AND TUMOR MICROVASCULATURE DENSITY IN RENAL CELL CARCINOMA
BR9815775A (pt) Anticorpos monoclonais anti-antìgeno carcinoembriÈnico (cea) humanizados de elevada afinidade
Lee et al. The Study of Expression of p53 Protein and Its Clinical Significance in Transitional Cell Carcinoma of the Urinary Bladder